Frankfurt am Main, May 9, 2017 – amp biosimilars AG (ISIN: DE000A0SMU87, WKN A0SMU8), listed on Munich Stock Exchange’s Open Market, held its extraordinary general meeting on May 8, in Berlin with 72.43 percent of the share capital represented. All management proposals were accepted unanimously.Read More
Frankfurt am Main, April 3, 2017 – amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has successfully completed its share capital increase resolved today, with approval of the supervisory board, from EUR 2,050,000.00 to EUR 2,075,000.00 by issuing 75,000 new no-par value bearer shares against cash contribution partially utilizing the existing authorized capital and excluding the shareholders’ subscription rights.Read More
Frankfurt am Main, March 30, 2017 – the management of amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has adjusted the company‘s business model.Read More
On March 14, 2017, Dr Stefan Elßer has appointed by the court of Frankfurt am Main to the Supervisory Board of amp biosimilars AG. Dr Elßer replaces Dr Thomas Zimmer whose term of office ended by the end of the annual general meeting 2016.Read More
Öffnen Sie die PDF-Datei hier.Read More
amp biosimilars AG (ISIN: DE000A0SMU87) today announced that Klaus K. Wilgenbus will lead the firm as the new CEO from July 1, 2016.
Click the link to download the pdf.Read More